Rockefeller Capital Management’s First Tracks Biotherapeutics TRAX Stock Holding History

Rockefeller Capital Management’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.35M	Buy	+116,939	New	+$2.19M	﹤0.01%	1308

Other funds holding TRAX

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Rockefeller Capital Management's TRAX Position: Q2 2026 in Review

Rockefeller Capital Management opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 116,939 shares worth $2.35M. The stake represents ﹤0.01% of the portfolio and ranks #1308 among its holdings.

89 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

Rockefeller Capital Management held 116,939 shares of First Tracks Biotherapeutics worth $2.35M as of Q2 2026.
First Tracks Biotherapeutics was a new Rockefeller Capital Management position in Q2 2026.
First Tracks Biotherapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #1308 holding.
89 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.